{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Dewdney.jpg|frameless|upright=0.3|center]]
|<big>[[User:Summerdewdney|Summer B. Dewdney, MD]]<br>Chicago, IL</big>
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==[http://www.esmo.org/ ESMO]==
*'''2017:''' Marth et al. [https://www.esmo.org/Guidelines/Gynaecological-Cancers/Cervical-Cancer Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
===Older===
*'''2012:''' Colombo et al. [http://annonc.oxfordjournals.org/content/23/suppl_7/vii27.full.pdf+html Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf NCCN Guidelines - Cervical Cancer]

=Neoadjuvant chemotherapy=
==Cisplatin & Paclitaxel {{#subobject:fdd2df|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:7b5fcb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(03)00647-4/abstract Park et al. 2004]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 2 hours once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 60 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg PO 12 and 6 hours before [[Paclitaxel (Taxol)]]
*[[Cimetidine (Tagamet)]] 300 mg IV 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Diphenhydramine (Benadryl)]] 50 mg IV 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[:Category:Emesis_prevention|Antiemetics]] before and 3 days after chemotherapy 

'''10-day cycle for 3 cycles'''
====Subsequent treatment====
*Clinical response assessed after 3 cycles with pelvic examination and MRI. Treatment followed by [[Surgery#Cervical_cancer_surgery|surgery]] or radiation therapy.

===References===
# Park DC, Kim JH, Lew YO, Kim DH, Namkoong SE. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol. 2004 Jan;92(1):59-63. [http://www.gynecologiconcology-online.net/article/S0090-8258(03)00647-4/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14751139 PubMed]

==No neoadjuvant therapy==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/11/9/1175/146942 Herod et al. 2000]
| style="background-color:#1a9851" |Phase III (C)
|BIP
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.gynecologiconcology-online.net/article/S0090-8258(07)00264-8/fulltext Eddy et al. 2007 (GOG 141)]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin & Vincristine
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671094/ Katsumata et al. 2013 (JCOG 0102)]
| style="background-color:#1a9851" |Phase III (C)
|BOMP
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No systemic therapy prior to surgery.''
====Subsequent treatment====
*[[Surgery#Radical_hysterectomy|Radical hysterectomy]]
===References===
# Herod J, Burton A, Buxton J, Tobias J, Luesley D, Jordan S, Dunn J, Poole CJ. A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix. Ann Oncol. 2000 Sep;11(9):1175-81. [https://academic.oup.com/annonc/article/11/9/1175/146942 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11061615 PubMed]
# '''GOG 141:''' Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E, O'Connor D. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the Gynecologic Oncology Group. Gynecol Oncol. 2007 Aug;106(2):362-9. Epub 2007 May 9. [https://www.gynecologiconcology-online.net/article/S0090-8258(07)00264-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17493669 PubMed]
# '''JCOG 0102:''' Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T, Yasugi T, Yaegashi N, Yokota H, Kodama S, Mizunoe T, Hiura M, Kasamatsu T, Shibata T, Kamura T; Japan Clinical Oncology Group. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer. 2013 May 28;108(10):1957-63. Epub 2013 May 2. [https://www.nature.com/articles/bjc2013179 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671094/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23640393 PubMed]

=Definitive chemoradiotherapy for locally advanced disease=
==Carboplatin & RT {{#subobject:ea866d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:e0e770|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.gynecologiconcology-online.net/article/S0090-8258(06)00523-3/fulltext Veerasarn et al. 2006]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, UFT, RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] 100 mg/m<sup>2</sup> IV once per week
*Concurrent [[External_beam_radiotherapy|radiation therapy]]

'''One course'''
===References===
# Veerasarn V, Lorvidhaya V, Kamnerdsupaphon P, Suntornpong N, Sangruchi S, Lertsanguansinchai P, Khorprasert C, Sookpreedee L, Udompunturak S. A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: preliminary results. Gynecol Oncol. 2007 Jan;104(1):15-23. Epub 2006 Sep 25. [https://www.gynecologiconcology-online.net/article/S0090-8258(06)00523-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16996583 PubMed]

==Cisplatin & RT {{#subobject:89c649|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 40.8 Gy, no cap {{#subobject:63d249|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJM199904153401502 Rose et al. 1999 (GOG 120)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin.2C_Fluorouracil.2C_Hydroxyurea.2C_RT|Cisplatin, Fluorouracil, Hydroxyurea, RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Hydroxyurea_.26_RT|Hydroxyurea & RT]]
|style="background-color:#1a9850"|Superior OS
|-
|}
''This regimen was intended for stage IIB disease.''
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15, 22, 29, 36, '''given 4 hours before radiation'''
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 1.7 Gy x 24 fractions, for an initial dose of 40.8 Gy

'''5-week course, followed in 1 to 3 weeks by:'''

====Radiotherapy====
*40 Gy by [[Brachytherapy|intracavitary brachytherapy]], for a total dose of 80.8 Gy to point A
**Patients that could not receive brachytherapy underwent additional [[External_beam_radiotherapy|external beam radiation therapy]] for a total dose of 61.2 Gy

===Variant #2, 45 Gy, capped cisplatin {{#subobject:ff6bdc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199904153401503 Keys et al. 1999 (GOG 123)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|RT]]
|style="background-color:#1a9850"|Superior OS
|-
|[http://jco.ascopubs.org/content/23/33/8289.long Lanciano et al. 2005 (GOG 165)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Fluorouracil_.26_RT|Fluorouracil & RT]]
|style="background-color:#d9ef8b"|Might have superior ORR
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> (maximum dose of 70 mg) IV once per day on days 1, 8, 15, 22, 29, 36, '''given 4 hours before radiation'''
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 1.8 Gy x 25 fractions, for an initial dose of 45 Gy

'''5-week course, followed by:'''
====Radiotherapy====
*GOG 123: [[Brachytherapy]] 30 Gy to point A for a total dose of 75 Gy
*GOG 165: brachytherapy as follows:
**EITHER Low-dose rate [[Brachytherapy|intracavitary brachytherapy]] of 40 Gy to point A given in 1 to 2 fractions
**OR High-dose rate [[Brachytherapy|intracavitary brachytherapy]] of 30 Gy to point A given in 5 fractions, starting week 4 of XRT
**Parametrial boost of 5.4 to 9 Gy was administered to the involved parametrium after whole pelvic RT was complete
====Subsequent treatment====
*GOG 123: Adjuvant [[Surgery#Hysterectomy|hysterectomy]]

===Variant #3, 45 Gy, uncapped cisplatin {{#subobject:76bee5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912330/ DiSilvestro et al. 2014 (GOG 219)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, Tirapazamine, RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29, 36
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 1.8 Gy x 23 to 25 fractions, for an initial dose of 41.4 to 45 Gy

'''5-week course, followed by:'''

====Radiotherapy====
*35 to 43.6 Gy to point A by [[Brachytherapy|intracavitary implant with radium or its equivalent]]

===Variant #4, 45 Gy, no cap {{#subobject:9a0b6f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.20.4.966 Pearcey et al. 2002]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|RT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 1.8 Gy x 25 fractions, given 5 days per week, for an initial dose of 45 Gy

'''5-week course'''
====Subsequent treatment====
*Brachytherapy; see paper for details

===Variant #5, 50 Gy, no cap {{#subobject:72d63d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thegreenjournal.com/article/S0167-8140(16)00068-2/fulltext Lutgens et al. 2016 (RADCHOC)]
|style="background-color:#1a9851"|Phase III (C)
|RT-HT
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2671607 Shrivastava et al. 2018 (CRACx)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|RT]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV once per week during radiation
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 2.0 Gy x 25 fractions given 5 days per week, for a dose of 50 Gy

====Supportive medications====
*[[Ondansetron (Zofran)]] 16 mg (route not specified) prior to chemotherapy
*[[Dexamethasone (Decadron)]] 8 mg (route not specified) prior to chemotherapy
*Pre- and post- cisplatin hydration

'''5-week course, followed by:'''

====Radiotherapy====
*See paper for details

===Variant #6, 50.4 Gy, no cap {{#subobject:b23457|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/29/13/1678.long Dueñas-González et al. 2011 (B9E-MC-JHQS)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Gemcitabine.2C_RT|Cisplatin, Gemcitabine, RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://academic.oup.com/annonc/article/23/9/2259/340469 Sehouli et al. 2012]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin & Paclitaxel, then RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15, 22, 29, 36, '''1 to 2 hours before radiation'''
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 1.8 Gy x 28 fractions given 5 days per week, for an initial dose of 50.4 Gy

'''6-week course, followed by:'''

====Radiotherapy====
*[[Brachytherapy]] with cesium-137, with 30 to 35 Gy delivered to point A

===Variant #7, 51 Gy, no cap {{#subobject:439228|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJM199904153401502 Rose et al. 1999 (GOG 120)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin.2C_Fluorouracil.2C_Hydroxyurea.2C_RT|Cisplatin, Fluorouracil, Hydroxyurea, RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Hydroxyurea_.26_RT|Hydroxyurea & RT]]
|style="background-color:#1a9850"|Superior OS
|-
|}
''This regimen was intended for stage III or IVA disease.''
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15, 22, 29, 36, '''4 hours before radiation'''
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 1.7 Gy x 30 fractions, for an initial dose of 51 Gy

'''6-week course, followed in 1 to 3 weeks by:'''

====Radiotherapy====
*30 Gy by [[Brachytherapy|intracavitary brachytherapy]], for a total dose of 81 Gy to point A
**Patients that could not receive brachytherapy underwent additional [[External_beam_radiotherapy|external beam radiation therapy]] for a total dose of 61.2 Gy

===References===
# '''GOG 120:''' Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1144-53. [https://www.nejm.org/doi/full/10.1056/NEJM199904153401502 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10202165 PubMed]
## '''Update:''' Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, Insalaco S; Gynecologic Oncology Group. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Jul 1;25(19):2804-10. Epub 2007 May 14. [http://jco.ascopubs.org/content/25/19/2804.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17502627 PubMed]
# '''GOG 123:''' Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL, Gersell D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999 Apr 15;340(15):1154-61. [https://www.nejm.org/doi/full/10.1056/NEJM199904153401503 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10202166 PubMed]
# '''NCIC CTG:''' Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002 Feb 15;20(4):966-72. [http://ascopubs.org/doi/full/10.1200/JCO.2002.20.4.966 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11844818 PubMed]
# '''GOG 165:''' Lanciano R, Calkins A, Bundy BN, Parham G, Lucci JA 3rd, Moore DH, Monk BJ, O'Connor DM. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol. 2005 Nov 20;23(33):8289-95. Epub 2005 Oct 17. [http://jco.ascopubs.org/content/23/33/8289.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16230678 PubMed]
<!-- Presented in part on the clinical trial registry located at ClinicalTrials.gov (identification No. NCT00191100), on the Lilly Clinical Trial Registry (www.lillytrials.com: trial identification No. 4015), and at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL. -->
# '''B9E-MC-JHQS:''' Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011 May 1;29(13):1678-85. Epub 2011 Mar 28. [http://jco.ascopubs.org/content/29/13/1678.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21444871 PubMed]
# Sehouli J, Runnebaum IB, Fotopoulou C, Blohmer U, Belau A, Leber H, Hanker LC, Hartmann W, Richter R, Keyver-Paik MD, Oberhoff C, Heinrich G, du Bois A, Olbrich C, Simon E, Friese K, Kimmig R, Boehmer D, Lichtenegger W, Kuemmel S. A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. Ann Oncol. 2012 Sep;23(9):2259-64. Epub 2012 Feb 21. [https://academic.oup.com/annonc/article/23/9/2259/340469 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22357252 PubMed]
# '''GOG 219:''' DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Steinhoff MM, Monk BJ. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol. 2014 Feb 10;32(5):458-64. Epub 2014 Jan 6. [http://ascopubs.org/doi/full/10.1200/JCO.2013.51.4265 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912330/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24395863 PubMed]
# '''RADCHOC:''' Lutgens LC, Koper PC, Jobsen JJ, van der Steen-Banasik EM, Creutzberg CL, van den Berg HA, Ottevanger PB, van Rhoon GC, van Doorn HC, Houben R, van der Zee J. Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial. Radiother Oncol. 2016 Sep;120(3):378-382. Epub 2016 Feb 17. [https://www.thegreenjournal.com/article/S0167-8140(16)00068-2/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26897513 PubMed]
# '''CRACx:''' Shrivastava S, Mahantshetty U, Engineer R, Chopra S, Hawaldar R, Hande V, Kerkar RA, Maheshwari A, Shylasree TS, Ghosh J, Bajpai J, Gurram L, Gulia S, Gupta S; Gynecologic Disease Management Group. Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix: a randomized clinical trial. JAMA Oncol. 2018 Apr 1;4(4):506-513. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2671607 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/29423520 PubMed]

==Cisplatin, Fluorouracil, RT {{#subobject:7fff9b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 70/4000 x 4 {{#subobject:749e5d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/17/5/1339.long Whitney et al. 1999 (GOG 85/SWOG 8695)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Hydroxyurea_.26_RT|Hydroxyurea & RT]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[http://jco.ascopubs.org/content/18/8/1606.long Peters et al. 2000 (GOG 109/SWOG-8797)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|Radiation therapy]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 70 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose: 4000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 1.7 Gy x 29 fractions given 5 days per week, for a total dose of 49.3 Gy, starting on cycle 1 day 1
**Patients with positive high common iliac lymph nodes also received 1.5 Gy x 30 fractions given 5 days per week, for a total dose of 45 Gy

'''21-day cycle for 4 cycles'''

===Variant #2, 75/4000 x 3 {{#subobject:16dd3c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJM199904153401501 Morris et al. 1999]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|Radiation therapy]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 4 hours once on day 1, '''given first'''
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose: 4000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 1.8 Gy x 25 fractions given 5 days per week, for a total dose of 45 Gy, starting on cycle 1 day 0 or 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*Brachytherapy (see paper for details)
===References===
# Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1137-43. [https://www.nejm.org/doi/10.1056/NEJM199904153401501 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10202164 PubMed]
# '''GOG 85/SWOG 8695:''' Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL, Liao SY. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999 May;17(5):1339-48. [http://jco.ascopubs.org/content/17/5/1339.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10334517 PubMed]
# '''GOG 109/SWOG-8797:''' Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000 Apr;18(8):1606-13. [http://jco.ascopubs.org/content/18/8/1606.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10764420 PubMed]

==Cisplatin, Fluorouracil, Hydroxyurea, RT {{#subobject:670a50|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy

===Regimen {{#subobject:bc5f6d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJM199904153401502 Rose et al. 1999 (GOG 120)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_RT|Cisplatin & RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Hydroxyurea_.26_RT|Hydroxyurea & RT]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*[[Hydroxyurea (Hydrea)]] 2000 mg/m<sup>2</sup> PO two times per week, '''2 hours before radiation on weeks 1 to 6'''
*Concurrent [[External_beam_radiotherapy|radiation therapy]] as follows:
**Stage IIB patients received 1.7 Gy x 24 fractions, for an initial dose of 40.8 Gy
**Stage III or IVA disease received 1.7 Gy x 30 fractions, for an initial dose of 51 Gy

'''28-day cycle for 2 cycles, then:'''

====Radiotherapy====
*Stage IIB patients received 40 Gy by [[Brachytherapy|intracavitary brachytherapy]], for a total dose of 80.8 Gy to point A
*Stage III or IVA disease received 30 Gy by [[Brachytherapy|intracavitary brachytherapy]], for a total dose of 81 Gy to point A
**Patients that could not receive brachytherapy underwent additional [[External_beam_radiotherapy|external beam radiation therapy]] for a total dose of 61.2 Gy

===References===
# '''GOG 120:''' Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1144-53. [https://www.nejm.org/doi/full/10.1056/NEJM199904153401502 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10202165 PubMed]
## '''Update:''' Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, Insalaco S; Gynecologic Oncology Group. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Jul 1;25(19):2804-10. Epub 2007 May 14. [http://jco.ascopubs.org/content/25/19/2804.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17502627 PubMed]

==Cisplatin, Gemcitabine, RT {{#subobject:8df5df|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy

===Regimen {{#subobject:342f7f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/29/13/1678.long Dueñas-González et al. 2011 (B9E-MC-JHQS)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_RT|Cisplatin & RT]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[https://academic.oup.com/annonc/article/24/8/2043/196760 Cetina et al. 2013]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15, 22, 29, 36, '''given first, 1 to 2 hours before radiation'''
*[[Gemcitabine (Gemzar)]] 125 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1, 8, 15, 22, 29, 36, '''given second, 1 to 2 hours before radiation'''
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 1.8 Gy x 28 fractions given 5 days per week, for an initial dose of 50.4 Gy

'''6-week course'''
====Subsequent treatment====
*B9E-MC-JHQS: [[#Radiation_therapy_2|Brachytherapy]] (30 to 35 Gy delivered to point A), then [[#Cisplatin_.26_Gemcitabine|adjuvant cisplatin & gemcitabine]], in 2 weeks
*Cetina et al. 2013: [[#Radiation_therapy_2|Brachytherapy]] verus [[Surgery#Radical_hysterectomy|radical hysterectomy]]

===References===
<!-- Presented in part on the clinical trial registry located at ClinicalTrials.gov (identification No. NCT00191100), on the Lilly Clinical Trial Registry (www.lillytrials.com: trial identification No. 4015), and at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL. -->
# '''B9E-MC-JHQS:''' Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011 May 1;29(13):1678-85. Epub 2011 Mar 28. [http://jco.ascopubs.org/content/29/13/1678.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21444871 PubMed]
# Cetina L, González-Enciso A, Cantú D, Coronel J, Pérez-Montiel D, Hinojosa J, Serrano A, Rivera L, Poitevin A, Mota A, Trejo E, Montalvo G, Muñoz D, Robles-Flores J, de la Garza J, Chanona J, Jiménez-Lima R, Wegman T, Dueñas-González A. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2-IIB cervical cancer patients. Ann Oncol. 2013 Aug;24(8):2043-7. Epub 2013 Apr 21. [https://academic.oup.com/annonc/article/24/8/2043/196760 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23609186 PubMed]

==Fluorouracil & RT {{#subobject:e9a589|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy

===Regimen {{#subobject:38087d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/33/8289.long Lanciano et al. 2005 (GOG 165)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_RT|Cisplatin & RT]]
|style="background-color:#fee08b"|Might have inferior ORR
|-
|}
====Chemoradiotherapy====
*[[Fluorouracil (5-FU)]] 225 mg/m<sup>2</sup>/day IV continuous infusion over five days per week x 6 weeks (total dose: 6750 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy x 25 fractions, for an initial dose of 40.8 Gy

'''6-week course, followed by:'''

====Radiotherapy====
**EITHER Low-dose rate [[Brachytherapy|intracavitary brachytherapy]] of 40 Gy to point A given in 1 to 2 fractions
**OR High-dose rate [[Brachytherapy|intracavitary brachytherapy]] of 30 Gy to point A given in 5 fractions, starting week 4 of XRT
*Parametrial boost of 5.4 to 9 Gy was administered to the involved parametrium after whole pelvic RT was complete

===References===
# '''GOG 165:''' Lanciano R, Calkins A, Bundy BN, Parham G, Lucci JA 3rd, Moore DH, Monk BJ, O'Connor DM. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol. 2005 Nov 20;23(33):8289-95. Epub 2005 Oct 17. [http://jco.ascopubs.org/content/23/33/8289.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16230678 PubMed]

==Fluorouracil, Mitomycin, RT {{#subobject:e20bf8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:b6a567|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.redjournal.org/article/S0360-3016(02)04405-X/fulltext Lorvidhava et al. 2003]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|RT]]
| style="background-color:#1a9850" |Superior DFS
|-
|}
''Here for historic reference.''
====Chemoradiotherapy====
*[[Fluorouracil (5-FU)]]
*[[Mitomycin (Mutamycin)]]
*Concurrent [[External_beam_radiotherapy|radiation therapy]]

===References===
# Lorvidhaya V, Chitapanarux I, Sangruchi S, Lertsanguansinchai P, Kongthanarat Y, Tangkaratt S, Visetsiri E. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1226-32. [https://www.redjournal.org/article/S0360-3016(02)04405-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12654431 PubMed]

==Hydroxyurea & RT {{#subobject:b93f37|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy

===Regimen {{#subobject:176533|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.redjournal.org/article/0360-3016(79)91209-4/abstract Hreshchyshyn et al. 1979 (GOG 04)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|Radiation therapy]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJM199904153401502 Rose et al. 1999 (GOG 120)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin_.26_RT|Cisplatin & RT]]
|style="background-color:#d73027"|Inferior OS
|-
|2. [[#Cisplatin.2C_Fluorouracil.2C_Hydroxyurea.2C_RT|Cisplatin, Fluorouracil, Hydroxyurea, RT]]
|style="background-color:#d73027"|Inferior OS
|-
|[http://jco.ascopubs.org/content/17/5/1339.long Whitney et al. 1999 (GOG 85/SWOG 8695)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT|Cisplatin, Fluorouracil, RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Chemoradiotherapy====
*[[Hydroxyurea (Hydrea)]] 2000 mg/m<sup>2</sup> PO two times per week, '''2 hours before radiation on weeks 1 to 6'''
*Concurrent [[External_beam_radiotherapy|radiation therapy]] as follows:
**Stage IIB patients received 1.7 Gy x 24 fractions, for an initial dose of 40.8 Gy
**Stage III or IVA disease received 1.7 Gy x 30 fractions, for an initial dose of 51 Gy

'''6-week course, followed in 1 to 3 weeks by:'''

====Radiotherapy====
*Stage IIB patients received 40 Gy by [[Brachytherapy|intracavitary brachytherapy]], for a total dose of 80.8 Gy to point A
*Stage III or IVA disease received 30 Gy by [[Brachytherapy|intracavitary brachytherapy]], for a total dose of 81 Gy to point A
**Patients that could not receive brachytherapy underwent additional [[External_beam_radiotherapy|external beam radiation therapy]] for a total dose of 61.2 Gy

===References===
# Hreshchyshyn MM, Aron BS, Boronow RC, Franklin EW 3rd, Shingleton HM, Blessing JA. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys. 1979 Mar;5(3):317-22. [http://www.redjournal.org/article/0360-3016(79)91209-4/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/110744 PubMed]
# '''GOG 120:''' Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1144-53. [https://www.nejm.org/doi/full/10.1056/NEJM199904153401502 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10202165 PubMed]
## '''Update:''' Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, Insalaco S; Gynecologic Oncology Group. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Jul 1;25(19):2804-10. Epub 2007 May 14. [http://jco.ascopubs.org/content/25/19/2804.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17502627 PubMed]
# '''GOG 85/SWOG 8695:''' Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL, Liao SY. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999 May;17(5):1339-48. [http://jco.ascopubs.org/content/17/5/1339.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10334517 PubMed]

==Radiation therapy {{#subobject:b13dbe|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:98b535|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.redjournal.org/article/0360-3016(79)91209-4/abstract Hreshchyshyn et al. 1979 (GOG 04)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Hydroxyurea_.26_RT|Hydroxyurea & RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.nejm.org/doi/10.1056/NEJM199904153401501 Morris et al. 1999]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_RT|Cisplatin & RT]]
|style="background-color:#d73027"|Inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199904153401503 Keys et al. 1999 (GOG 123)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_RT|Cisplatin & RT]]
|style="background-color:#d73027"|Inferior OS
|-
|[http://jco.ascopubs.org/content/18/8/1606.long Peters et al. 2000 (GOG 109/SWOG-8797)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT|Cisplatin, Fluorouracil, RT]]
|style="background-color:#d73027"|Inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.20.1.179 Benedetti-Panici et al. 2002]
|style="background-color:#1a9851"|Phase III (C)
|NACT, then surgery
|style="background-color:#d73027"|Inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.20.4.966 Pearcey et al. 2002]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_RT|Cisplatin & RT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1111/ajco.12078 Srivastava et al. 2013]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_RT|Cisplatin & RT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2671607 Shrivastava et al. 2018 (CRACx)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_RT|Cisplatin & RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
''Demonstrably inferior; here for reference purposes only.''
====Radiotherapy====
*[[External beam radiotherapy]]
====Subsequent treatment====
*Hreshchyshyn et al. 1979 & GOG 123: adjuvant [[Surgery#Hysterectomy|hysterectomy]]

===References===
# '''GOG 04:''' Hreshchyshyn MM, Aron BS, Boronow RC, Franklin EW 3rd, Shingleton HM, Blessing JA. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys. 1979 Mar;5(3):317-22. [http://www.redjournal.org/article/0360-3016(79)91209-4/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/110744 PubMed]
# Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1137-43. [https://www.nejm.org/doi/10.1056/NEJM199904153401501 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10202164 PubMed]
# '''GOG 123:''' Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL, Gersell D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999 Apr 15;340(15):1154-61. [https://www.nejm.org/doi/full/10.1056/NEJM199904153401503 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10202166 PubMed]
# '''GOG 109/SWOG-8797:''' Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000 Apr;18(8):1606-13. [http://jco.ascopubs.org/content/18/8/1606.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10764420 PubMed]
# Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C, Landoni F. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol. 2002 Jan 1;20(1):179-88. [http://ascopubs.org/doi/full/10.1200/JCO.2002.20.1.179 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11773168 PubMed]
# Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002 Feb 15;20(4):966-72. [http://ascopubs.org/doi/full/10.1200/JCO.2002.20.4.966 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11844818 PubMed]
# Srivastava K, Paul S, Chufal KS, Shamsundar SD, Lal P, Pant MC, Bhatt M, Singh S, Gupta R. Concurrent chemoradiation versus radiotherapy alone in cervical carcinoma: a randomized phase III trial. Asia Pac J Clin Oncol. 2013 Dec;9(4):349-56. Epub 2013 May 27. [https://onlinelibrary.wiley.com/doi/abs/10.1111/ajco.12078 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23710586 PubMed]
# '''CRACx:''' Shrivastava S, Mahantshetty U, Engineer R, Chopra S, Hawaldar R, Hande V, Kerkar RA, Maheshwari A, Shylasree TS, Ghosh J, Bajpai J, Gurram L, Gulia S, Gupta S; Gynecologic Disease Management Group. Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix: a randomized clinical trial. JAMA Oncol. 2018 Apr 1;4(4):506-513. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2671607 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/29423520 PubMed]

=Adjuvant therapy=
==Carboplatin & Ifosfamide {{#subobject:3c6ded|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:93caff|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.30.4899 Blohmer et al. 2011 (NOGGO-AGO)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#NOGGO-AGO|See link]]
| style="background-color:#fee08b" |[[Complex_multipart_regimens#NOGGO-AGO|See link]]
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Preceding treatment====
*[[Surgery#Radical_hysterectomy|Wertheim-Meigs radical abdominal hysterectomy]]
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 4 IV over 60 minutes once on day 1
*[[Ifosfamide (Ifex)]] 1600 mg/m<sup>2</sup> IV over 6 hours once per day on days 1 to 3
====Supportive medications====
*[[Mesna (Mesnex)]] 1600 mg/m<sup>2</sup> IV over 6 hours once per day on days 1 to 3, with [[Ifosfamide (Ifex)]]

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Radiation_therapy_2|Pelvic EBRT]] x 50.4 Gy
===References===
# Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J Clin Oncol. 2011 Oct 1;29(28):3791-7. Epub 2011 Aug 22. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.4899 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21860000 PubMed]

==Cisplatin & Gemcitabine {{#subobject:5de31f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c4c8f2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/29/13/1678.long Dueñas-González et al. 2011 (B9E-MC-JHQS)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Cisplatin.2C_Gemcitabine.2C_RT|Cisplatin, Gemcitabine, RT]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycle for 2 cycles'''

===References===
<!-- Presented in part on the clinical trial registry located at ClinicalTrials.gov (identification No. NCT00191100), on the Lilly Clinical Trial Registry (www.lillytrials.com: trial identification No. 4015), and at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL. -->
# '''B9E-MC-JHQS:''' Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011 May 1;29(13):1678-85. Epub 2011 Mar 28. [http://jco.ascopubs.org/content/29/13/1678.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21444871 PubMed]

==Radiation therapy {{#subobject:e34211|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:aa4d8e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.30.4899 Blohmer et al. 2011 (NOGGO-AGO)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#NOGGO-AGO|See link]]
| style="background-color:#fee08b" |[[Complex_multipart_regimens#NOGGO-AGO|See link]]
|-
|}
====Preceding treatment====
*[[Surgery#Cervical_cancer_surgery|Surgery]], then [[#Carboplatin_.26_Ifosfamide|Carboplatin & Ifosfamide]] x 4
====Radiotherapy====
*[[External beam radiotherapy]] in 1.80 Gy fractions, 5 days per week, for a total dose of 50.4 Gy
*If resection margins positive, patients received one of the following:
**EBRT boost of 2 x 5 Gy
**Low-dose brachytherapy

'''One course'''

===References===
# '''NOGGO-AGO:''' Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J Clin Oncol. 2011 Oct 1;29(28):3791-7. Epub 2011 Aug 22. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.4899 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21860000 PubMed]

=Persistent, recurrent, or metastatic disease, first-line therapy=

==Carboplatin monotherapy {{#subobject:fae1e7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:fe1b36|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/0090-8258(90)90262-J/fulltext Weiss et al. 1990]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] 400 mg/m<sup>2</sup> IV once on day 1

'''28-day cycles'''

===References===
# Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, Alberts DS. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol. 1990 Dec;39(3):332-6. [http://www.gynecologiconcology-online.net/article/0090-8258(90)90262-J/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2258080 PubMed]

==Carboplatin & Docetaxel {{#subobject:39c86d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9fb5d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(04)00975-8/abstract Nagao et al. 2005]
|style="background-color:#ffffbe"|Pilot, <20 pts
|-
|[https://insights.ovid.com/pubmed?pmid=21370599 Takekida et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 60 minutes once on day 1, '''given second'''
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first'''

====Supportive medications====
*[[Dexamethasone (Decadron)]]
*[[Ondansetron (Zofran)]] or [[Granisetron]]
*[[Filgrastim (Neupogen)]] 5 mcg/kg once per day for patients with grade 4 neutropenia or febrile neutropenia

'''21-day cycle for up to 6 cycles (Takekida et al. 2010) or indefinitely (Nagao et al. 2005)'''

===References===
# Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, Kohno I. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer: a pilot study. Gynecol Oncol. 2005 Mar;96(3):805-9. [http://www.gynecologiconcology-online.net/article/S0090-8258(04)00975-8/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15721429 PubMed]
# Takekida S, Fujiwara K, Nagao S, Yamaguchi S, Yoshida N, Kitada F, Kigawa J, Terakawa N, Nishimura R. Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer. Int J Gynecol Cancer. 2010 Dec;20(9):1563-8. [https://insights.ovid.com/pubmed?pmid=21370599 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21370599 PubMed]

==Carboplatin & Paclitaxel {{#subobject:be30d5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TC: '''<u>T</u>'''axol (Paclitaxel) & '''<u>C</u>'''arboplatin
===Regimen {{#subobject:7668ec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://journals.lww.com/ijgc/pages/articleviewer.aspx?year=2009&issue=05000&article=00049&type=abstract Pectasides et al. 2009]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.58.4391 Kitagawa et al. 2015 (JCOG0505)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Paclitaxel_2|Cisplatin & Paclitaxel]]
|style="background-color:#eeee01"|Non-inferior OS
|-
|}
''Note: Pectasides et al. 2009 allowed the regimen to be given up to 9 cycles.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 60 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for 6 cycles'''

===References===
# Pectasides D, Fountzilas G, Papaxoinis G, Pectasides E, Xiros N, Sykiotis C, Koumarianou A, Psyrri A, Panayiotides J, Economopoulos T. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer. Int J Gynecol Cancer. 2009 May;19(4):777-81. [http://journals.lww.com/ijgc/pages/articleviewer.aspx?year=2009&issue=05000&article=00049&type=abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19509587 PubMed]
# '''JCOG0505:''' Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015 Jul 1;33(19):2129-35. Epub 2015 Mar 2. [http://ascopubs.org/doi/full/10.1200/JCO.2014.58.4391 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25732161 PubMed]

==Cisplatin monotherapy {{#subobject:117c0b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a3542f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/498154 Thigpen et al. 1979]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1985.3.8.1079 Bonomi et al. 1985 (GOG 43)]
|style="background-color:#1a9851"|Phase III (C)
|1. Higher-dose cisplatin<br> 2. Higher-dose cisplatin, split doses
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.gynecologiconcology-online.net/article/S0090-8258(89)80033-2/pdf Thigpen et al. 1989 (GOG 64)]
|style="background-color:#1a9851"|Phase III (C)
|CI Cisplatin
| style="background-color:#ffffbf" |Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/10.1200/jco.1997.15.1.165 Omura et al. 1997 (GOG 110)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Ifosfamide|Cisplatin & Ifosfamide]]
|style="background-color:#d73027"|Inferior PFS
|-
|Cisplatin & Mitolactol
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/12/7/967/150654 Vermorken et al. 2001]
|style="background-color:#1a9851"|Phase III (C)
|BEMP
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/22/15/3113.long Moore et al. 2004 (GOG 169)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Paclitaxel_2|Cisplatin & Paclitaxel]]
|style="background-color:#d73027"|Inferior PFS
|-
|rowspan=2|[http://jco.ascopubs.org/content/23/21/4626.long Long et al. 2005 (GOG 179)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin_.26_Topotecan|Cisplatin & Topotecan]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|2. MVAC
|style="background-color:#d3d3d3"|Not reported
|-
|[https://www.nature.com/articles/s41416-018-0206-7 Aoki et al. 2018]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & S-1
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles; if not responding, given for maximum of 6 cycles'''

===References===
# Thigpen T, Shingleton H, Homesley H, LaGasse L, Blessing J. cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1549-55. [https://www.ncbi.nlm.nih.gov/pubmed/498154 PubMed]
# '''GOG 43:''' Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985 Aug;3(8):1079-85. [http://ascopubs.org/doi/abs/10.1200/JCO.1985.3.8.1079 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3894589 PubMed]
# '''GOG 64:''' Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr, Hatch KD. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1989 Feb;32(2):198-202. [https://www.gynecologiconcology-online.net/article/S0090-8258(89)80033-2/pdf link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2910782 PubMed]
# '''GOG 110:''' Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, Anderson B. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997 Jan;15(1):165-71. [http://ascopubs.org/doi/10.1200/jco.1997.15.1.165 link to original article] '''contains protocol''' [http://ncbi.nlm.nih.gov/pubmed/8996138 PubMed]
# Vermorken JB, Zanetta G, De Oliveira CF, van der Burg ME, Lacave AJ, Teodorovic I, Boes GH, Colombo N. Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. Ann Oncol. 2001 Jul;12(7):967-74. [https://academic.oup.com/annonc/article/12/7/967/150654 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11521804 PubMed]
# '''GOG 169:''' Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004 Aug 1;22(15):3113-9. [http://jco.ascopubs.org/content/22/15/3113.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15284262 PubMed]
<!-- Presented in abstract form at the Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, February 8, 2004. -->
# '''GOG 179:''' Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005 Jul 20;23(21):4626-33. Epub 2005 May 23. [http://jco.ascopubs.org/content/23/21/4626.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15911865 PubMed]
# Aoki Y, Ochiai K, Lim S, Aoki D, Kamiura S, Lin H, Katsumata N, Cha SD, Kim JH, Kim BG, Hirashima Y, Fujiwara K, Kim YT, Kim SM, Chung HH, Chang TC, Kamura T, Takizawa K, Takeuchi M, Kang SB. Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer. Br J Cancer. 2018 Aug;119(5):530-537. Epub 2018 Aug 3. [https://www.nature.com/articles/s41416-018-0206-7 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30072745 PubMed]

==Cisplatin & Gemcitabine {{#subobject:fbbad7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GC: '''<u>G</u>'''emcitabine, '''<u>C</u>'''isplatin
===Regimen {{#subobject:2e2004|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754911/ Monk et al. 2009 (GOG 204)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_Paclitaxel_2|Cisplatin & Paclitaxel]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|2. [[#Cisplatin_.26_Topotecan|Cisplatin & Topotecan]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#Cisplatin_.26_Vinorelbine|Cisplatin & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycles'''

===References===
<!-- Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL. -->
# '''GOG 204:''' Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Oct 1;27(28):4649-55. Epub 2009 Aug 31. [http://jco.ascopubs.org/content/27/28/4649.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754911/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19720909 PubMed]

==Cisplatin & Ifosfamide {{#subobject:3c6ded|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:93caff|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2 |[http://ascopubs.org/doi/10.1200/jco.1997.15.1.165 Omura et al. 1997 (GOG 110)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_monotherapy|Cisplatin]]
| style="background-color:#1a9850" |Superior PFS
|-
|Cisplatin & Mitolactol
| style="background-color:#d3d3d3" |Not reported
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.07.045 Bloss et al. 2002 (GOG 149)]
|style="background-color:#1a9851"|Phase III (C)
|CIB
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]]
*[[Ifosfamide (Ifex)]]

===References===
# '''GOG 110:''' Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, Anderson B. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997 Jan;15(1):165-71. [http://ascopubs.org/doi/10.1200/jco.1997.15.1.165 link to original article] '''contains protocol''' [http://ncbi.nlm.nih.gov/pubmed/8996138 PubMed]
# '''GOG 149:''' Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2002 Apr 1;20(7):1832-7. [http://ascopubs.org/doi/full/10.1200/JCO.2002.07.045 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11919241 PubMed]

==Cisplatin & Mitomycin {{#subobject:c97b6f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:6e84ee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ejcancer.com/article/S0959-8049(01)00178-2/fulltext Wagenaar et al. 2001]
|style="background-color:#91cf61"|Phase II
| style="background-color:#8c96c6" |ORR: 42% (95% CI: 26-61%)
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1, '''given second'''
*[[Mitomycin (Mutamycin)]] 6 mg/m<sup>2</sup> IV push on day 1, '''given first'''

====Supportive medications====
*1 liter NS over 1 hour before chemotherapy, and 1 liter NS over 1 hour after [[Cisplatin (Platinol)]]
*[[Furosemide (Lasix)]] prior to chemotherapy
*[[Mannitol]] IV push prior to [[Cisplatin (Platinol)]]

'''28-day cycle for 9 cycles'''

===References===
# Wagenaar HC, Pecorelli S, Mangioni C, van der Burg ME, Rotmensz N, Anastasopoulou A, Zola P, Veenhof CH, Lacave AJ, Neijt JP, van Oosterom AT, Einhorn N, Vermorken JB. Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix: a European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. Eur J Cancer. 2001 Sep;37(13):1624-8. [https://www.ejcancer.com/article/S0959-8049(01)00178-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11527687 PubMed]

==Cisplatin & Paclitaxel {{#subobject:aab02e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PC: '''<u>P</u>'''aclitaxel & '''<u>C</u>'''isplatin
<br>CP: '''<u>C</u>'''isplatin & '''<u>P</u>'''aclitaxel
<br>TP: '''<u>T</u>'''axol (Paclitaxel) & '''<u>P</u>'''latinol (Cisplatin)
===Variant #1, 50/135, 3 hr paclitaxel {{#subobject:PYV4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://www.nejm.org/doi/full/10.1056/NEJMoa1309748 Tewari et al. 2014 (GOG 240)]
|rowspan=3 style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin.2C_Paclitaxel.2C_Bevacizumab|Cisplatin, Paclitaxel, Bevacizumab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|2. [[#Paclitaxel_.26_Topotecan|Paclitaxel & Topotecan]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#Paclitaxel.2C_Topotecan.2C_Bevacizumab|Paclitaxel, Topotecan, Bevacizumab]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles until CR or indefinitely'''

===Variant #2, 50/135, CI paclitaxel {{#subobject:bd6f7b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/15/3113.long Moore et al. 2004 (GOG 169)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_monotherapy|Cisplatin]]
|style="background-color:#1a9850"|Superior PFS
|-
|rowspan=3|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754911/ Monk et al. 2009 (GOG 204)]
|rowspan=3 style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin_.26_Gemcitabine_2|Cisplatin & Gemcitabine]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|2. [[#Cisplatin_.26_Topotecan|Cisplatin & Topotecan]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#Cisplatin_.26_Vinorelbine|Cisplatin & Vinorelbine]]
|style="background-color:#d9ef8b"|Might have superior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.58.4391 Kitagawa et al. 2015 (JCOG0505)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_Paclitaxel|Carboplatin & Paclitaxel]]
|style="background-color:#eeee01"|Non-inferior OS
|-
|}
''Note: patients in JCOG0505 received a maximum of 6 cycles.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 2
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

====Supportive medications====
*(varies depending on reference):
*[[Dexamethasone (Decadron)]]
*[[Diphenhydramine (Benadryl)]]
*H2 receptor antagonist such as [[Cimetidine (Tagamet)]] or [[Ranitidine (Zantac)]]
*Prophylactic [[:Category:Emesis_prevention|antiemetics]].
*"Adequate IV hydration and electrolyte replacement"

'''21-day cycles; if not responding, given for maximum of 6 cycles.'''

===Variant #3, 50/175 {{#subobject:ccc92b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://www.nejm.org/doi/full/10.1056/NEJMoa1309748 Tewari et al. 2014 (GOG 240)]
|rowspan=3 style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin.2C_Paclitaxel.2C_Bevacizumab|Cisplatin, Paclitaxel, Bevacizumab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|2. [[#Paclitaxel_.26_Topotecan|Paclitaxel & Topotecan]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#Paclitaxel.2C_Topotecan.2C_Bevacizumab|Paclitaxel, Topotecan, Bevacizumab]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles until CR or indefinitely'''

===References===
# '''GOG 169:''' Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004 Aug 1;22(15):3113-9. [http://jco.ascopubs.org/content/22/15/3113.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15284262 PubMed]
<!-- Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL. -->
# '''GOG 204:''' Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Oct 1;27(28):4649-55. Epub 2009 Aug 31. [http://jco.ascopubs.org/content/27/28/4649.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754911/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19720909 PubMed]
# '''GOG 240:''' Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20;370(8):734-43. [https://www.nejm.org/doi/full/10.1056/NEJMoa1309748 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1309748/suppl_file/nejmoa1309748_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24552320 PubMed]
## '''Update:''' Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 7;390(10103):1654-1663. Epub 2017 Jul 27. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31607-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28756902 PubMed]
# '''JCOG0505:''' Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015 Jul 1;33(19):2129-35. Epub 2015 Mar 2. [http://ascopubs.org/doi/full/10.1200/JCO.2014.58.4391 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25732161 PubMed]

==Cisplatin, Paclitaxel, Bevacizumab {{#subobject:PYR1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CP+Bev: '''<u>C</u>'''isplatin, '''<u>P</u>'''aclitaxel, '''<u>Bev</u>'''acizumab
===Variant #1, 135 mg/m<sup>2</sup> paclitaxel {{#subobject:PYV1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094/ Tewari et al. 2014 (GOG 240)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_Paclitaxel_2|Cisplatin & Paclitaxel]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|2. [[#Paclitaxel_.26_Topotecan|Paclitaxel & Topotecan]]
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|3. [[#Paclitaxel.2C_Topotecan.2C_Bevacizumab|Paclitaxel, Topotecan, Bevacizumab]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
''Note: efficacy marked with (*) based on 2017 update.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles until CR or indefinitely'''

===Variant #2, 175 mg/m<sup>2</sup> paclitaxel {{#subobject:ca025d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094/ Tewari et al. 2014 (GOG 240)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_Paclitaxel_2|Cisplatin & Paclitaxel]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|2. [[#Paclitaxel_.26_Topotecan|Paclitaxel & Topotecan]]
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|3. [[#Paclitaxel.2C_Topotecan.2C_Bevacizumab|Paclitaxel, Topotecan, Bevacizumab]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
''Note: efficacy marked with (*) based on 2017 update.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles until CR or indefinitely'''

===References===
# '''GOG 240:''' Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20;370(8):734-43. [https://www.nejm.org/doi/full/10.1056/NEJMoa1309748 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1309748/suppl_file/nejmoa1309748_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24552320 PubMed]
## '''Update:''' Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 7;390(10103):1654-1663. Epub 2017 Jul 27. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31607-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28756902 PubMed]

==Cisplatin & Topotecan {{#subobject:e399c6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TC: '''<u>T</u>'''opotecan, '''<u>C</u>'''isplatin
===Regimen {{#subobject:f703f4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/23/21/4626.long Long et al. 2005 (GOG 179)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_monotherapy|Cisplatin]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|2. MVAC
|style="background-color:#d3d3d3"|Not reported
|-
|rowspan=3|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754911/ Monk et al. 2009 (GOG 204)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_Gemcitabine_2|Cisplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_Paclitaxel_2|Cisplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|3. [[#Cisplatin_.26_Vinorelbine|Cisplatin & Vinorelbine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1, '''given second'''
*[[Topotecan (Hycamtin)]] 0.75 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 3, '''given first'''

'''21-day cycles; if not responding, given for maximum of 6 cycles'''

===References===
<!-- Presented in abstract form at the Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, February 8, 2004. -->
# '''GOG 179:''' Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005 Jul 20;23(21):4626-33. Epub 2005 May 23. [http://jco.ascopubs.org/content/23/21/4626.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15911865 PubMed]
<!-- Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL. -->
# '''GOG 204:''' Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Oct 1;27(28):4649-55. Epub 2009 Aug 31. [http://jco.ascopubs.org/content/27/28/4649.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754911/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19720909 PubMed]

==Cisplatin & Vinorelbine {{#subobject:176775|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VC: '''<u>V</u>'''inorelbine, '''<u>C</u>'''isplatin
===Regimen {{#subobject:e442f7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754911/ Monk et al. 2009 (GOG 204)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_Gemcitabine_2|Cisplatin & Gemcitabine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_Paclitaxel_2|Cisplatin & Paclitaxel]]
|style="background-color:#fee08b"|Might have inferior PFS
|-
|3. [[#Cisplatin_.26_Topotecan|Cisplatin & Topotecan]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycles; if not responding, given for maximum of 6 cycles'''

===References===
<!-- Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL. -->
# '''GOG 204:''' Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Oct 1;27(28):4649-55. Epub 2009 Aug 31. [http://jco.ascopubs.org/content/27/28/4649.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754911/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19720909 PubMed]

==Ifosfamide monotherapy {{#subobject:1d18ed|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:962339|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://link.springer.com/article/10.1007/BF00273403 Coleman et al. 1986]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ajog.org/article/S0002-9378(12)90824-8/pdf Sutton et al. 1993a]
|style="background-color:#91cf61"|Phase II
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(83)71084-X/abstract Sutton et al. 1993b]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once per day on days 1 to 5
**Dosage for patients with previous pelvic radiation or other chemotherapy is 1200 mg/m<sup>2</sup>
**Dose could be increased by 300 mg/m<sup>2</sup> or decreased by 20% depending on toxicity

====Supportive medications====
*[[Mesna (Mesnex)]] at 20% of ifosfamide dose (for example, 300 mg/m<sup>2</sup> for 1500 mg/m<sup>2</sup> dose of ifosfamide) IV given at 0, 4, and 8 hours after each dose of ifosfamide on days 1 to 5

'''21-day cycles'''

===References===
# Coleman RE, Harper PG, Gallagher C, Osborne R, Rankin EM, Silverstone AC, Slevin ML, Souhami RL, Tobias JS, Trask CW, Wiltshaw E. A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol. 1986;18(3):280-3. [https://link.springer.com/article/10.1007/BF00273403 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3802384 PubMed]
# Sutton GP, Blessing JA, McGuire WP, Patton T, Look KY. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):805-7. [https://www.ajog.org/article/S0002-9378(12)90824-8/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8456884 PubMed]
# Sutton GP, Blessing JA, DiSaia PJ, McGuire WP. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1993 Apr;49(1):48-50. [http://www.gynecologiconcology-online.net/article/S0090-8258(83)71084-X/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8482560 PubMed]

==Paclitaxel monotherapy {{#subobject:635f43|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 135 mg/m<sup>2</sup> {{#subobject:723bf0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/14/3/792.long McGuire et al. 1996]
|style="background-color:#91cf61"|Phase II
|-
|[http://jco.ascopubs.org/content/19/5/1275.long Curtin et al. 2001]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this was the dosage used for patients with previous pelvic radiation.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
**Dose could be changed to 110 or 200 mg/m<sup>2</sup> depending on toxicity

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg IV or PO 14 and 7 hours prior to paclitaxel
*[[Diphenhydramine (Benadryl)]] 50 mg IV 30 minutes prior to paclitaxel
*[[Ranitidine (Zantac)]] 50 mg IV 30 minutes prior to paclitaxel

'''21-day cycles'''

===Variant #2, 170 mg/m<sup>2</sup> {{#subobject:6eac87|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/14/3/792.long McGuire et al. 1996]
|style="background-color:#91cf61"|Phase II
|-
|[http://jco.ascopubs.org/content/19/5/1275.long Curtin et al. 2001]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 170 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1
**Dosage for patients with previous pelvic radiation was 135 mg/m<sup>2</sup>
**Dose could be changed to 110 or 200 mg/m<sup>2</sup> depending on toxicity

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg IV or PO 14 and 7 hours prior to paclitaxel
*[[Diphenhydramine (Benadryl)]] 50 mg IV 30 minutes prior to paclitaxel
*[[Ranitidine (Zantac)]] 50 mg IV 30 minutes prior to paclitaxel

'''21-day cycles'''

===Variant #3, 250 mg/m<sup>2</sup> {{#subobject:4c3e15|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://clincancerres.aacrjournals.org/content/2/8/1285.long Kudelka et al. 1996]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 250 mg/m<sup>2</sup> IV over 3 hours on day 1
**Dose could be changed to 275, 225, or 200 mg/m<sup>2</sup> depending on toxicity

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg PO 14 and 7 hours prior to paclitaxel
*[[Cimetidine (Tagamet)]] 300 mg IV 60 minutes prior to paclitaxel
*[[Diphenhydramine (Benadryl)]] 50 mg IV 60 minutes prior to paclitaxel
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 2, 24 hours after chemotherapy, given until day 19 or until ANC greater or equal to 10,000/uL

'''21-day cycles'''

===References===
# McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1996 Mar;14(3):792-5. [http://jco.ascopubs.org/content/14/3/792.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8622025 PubMed]
# Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, Loyer E, Rusinkiewicz J, Gacrama P, Fueger R, Kavanagh JJ. Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Clin Cancer Res. 1996 Aug;2(8):1285-8. [http://clincancerres.aacrjournals.org/content/2/8/1285.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9816298 PubMed] content property of [http://hemonc.org HemOnc.org]
## '''Update:''' Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, LoCoco S, Umbreit J, Delmore JE, Arbuck S, Loyer E, Gacrama P, Fueger R, Kavanagh JJ. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs. 1997 Aug;8(7):657-61. [https://www.ncbi.nlm.nih.gov/pubmed/9311440 PubMed]
# Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, Malfetano JH, Alvarez RD. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2001 Mar 1;19(5):1275-8. [http://jco.ascopubs.org/content/19/5/1275.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11230468 PubMed]

==Paclitaxel & Topotecan {{#subobject:PYR2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TP: '''<u>T</u>'''opotecan, '''<u>P</u>'''aclitaxel
===Regimen {{#subobject:PYV2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094/ Tewari et al. 2014 (GOG 240)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_Paclitaxel_2|Cisplatin & Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin.2C_Paclitaxel.2C_Bevacizumab|Cisplatin, Paclitaxel, Bevacizumab]]
|style="background-color:#d3d3d3"|Not reported
|-
|3. [[#Paclitaxel.2C_Topotecan.2C_Bevacizumab|Paclitaxel, Topotecan, Bevacizumab]]
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|}
''Note: per the initial report, topotecan & paclitaxel +/- bevacizumab regimens were "associated with a significantly higher risk of progression" as compared to cisplatin & paclitaxel +/- bevacizumab regimens. Efficacy marked with (*) is based on 2017 update.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1
*[[Topotecan (Hycamtin)]] 0.75 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''21-day cycles'''

===References===
# '''GOG 240:''' Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20;370(8):734-43. [https://www.nejm.org/doi/full/10.1056/NEJMoa1309748 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1309748/suppl_file/nejmoa1309748_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24552320 PubMed]
## '''Update:''' Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 7;390(10103):1654-1663. Epub 2017 Jul 27. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31607-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28756902 PubMed]

==Paclitaxel, Topotecan, Bevacizumab {{#subobject:PYR3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TP+Bev: '''<u>T</u>'''opotecan, '''<u>P</u>'''aclitaxel, '''<u>Bev</u>'''acizumab
===Regimen {{#subobject:PYV3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094/ Tewari et al. 2014 (GOG 240)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_Paclitaxel_2|Cisplatin & Paclitaxel]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Cisplatin.2C_Paclitaxel.2C_Bevacizumab|Cisplatin, Paclitaxel, Bevacizumab]]
|style="background-color:#d3d3d3"|Not reported
|-
|3. [[#Paclitaxel_.26_Topotecan|Paclitaxel & Topotecan]]
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|}
''Note: in the initial report, topotecan & paclitaxel +/- bevacizumab regimens were "associated with a significantly higher risk of progression" as compared to cisplatin & paclitaxel +/- bevacizumab regimens. Efficacy marked with (*) is based on the 2017 update.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1
*[[Topotecan (Hycamtin)]] 0.75 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# '''GOG 240:''' Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20;370(8):734-43. [https://www.nejm.org/doi/full/10.1056/NEJMoa1309748 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1309748/suppl_file/nejmoa1309748_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24552320 PubMed]
## '''Update:''' Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 7;390(10103):1654-1663. Epub 2017 Jul 27. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31607-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28756902 PubMed]

==Topotecan monotherapy {{#subobject:720120|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, q3wk {{#subobject:be1724|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(00)95807-4/abstract Bookman et al. 2000 (GOG 127-F)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Topotecan (Hycamtin)]] 1.5 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5

'''21-day cycles'''

===Variant #2, q4wk {{#subobject:469fbe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(00)96024-4/abstract Muderspach et al. 2001]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Topotecan (Hycamtin)]] 1.5 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5

'''28-day cycles'''

===References===
# Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Jun;77(3):446-9. [http://www.gynecologiconcology-online.net/article/S0090-8258(00)95807-4/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10831357 PubMed]
# Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Gxroup study. Gynecol Oncol. 2001 May;81(2):213-5. [http://www.gynecologiconcology-online.net/article/S0090-8258(00)96024-4/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11354055 PubMed]

==Vinorelbine monotherapy {{#subobject:b92b24|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e1af3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/16/3/1094.long Morris et al. 1998]
|style="background-color:#91cf61"|Phase II
|ORR: 18%
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once on day 1

'''7-day cycles'''

===References===
# Morris M, Brader KR, Levenback C, Burke TW, Atkinson EN, Scott WR, Gershenson DM. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol. 1998 Mar;16(3):1094-8. [http://jco.ascopubs.org/content/16/3/1094.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9508195 PubMed]

=Advanced or metastatic disease, subsequent lines of therapy=
==Bevacizumab monotherapy {{#subobject:1da8f9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:67b93c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667811/ Monk et al. 2009 (GOG 227-C)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
<!-- Presented in part at the 39th Annual Meeting of the Society of Gynecologic Oncologists, March 9-12, 2008, Tampa, FL. -->
# Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009 Mar 1;27(7):1069-74. Epub 2009 Jan 12. [http://jco.ascopubs.org/content/27/7/1069.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667811/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19139430 PubMed]

==Cisplatin & Gemcitabine {{#subobject:d9cdf3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GC: '''<u>G</u>'''emcitabine, '''<u>C</u>'''isplatin
===Regimen {{#subobject:684026|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(05)00789-4/abstract Brewer et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once on day 1, '''given first'''
*[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV once per day on days 1 & 8, '''given second'''

'''28-day cycles'''

===References===
# Brewer CA, Blessing JA, Nagourney RA, McMeekin DS, Lele S, Zweizig SL. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006 Feb;100(2):385-8. Epub 2005 Nov 4. [http://www.gynecologiconcology-online.net/article/S0090-8258(05)00789-4/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16271750 PubMed]

==Docetaxel monotherapy {{#subobject:95153c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1, 36 mg/m<sup>2</sup>, 3 weeks out of 4 {{#subobject:328695|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(08)00452-6/abstract Garcia et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 36 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO the evening before, morning of, and evening of each dose of docetaxel

'''28-day cycles'''

===Variant #2, 100 mg/m<sup>2</sup>, q3wk {{#subobject:744f01|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=2007&issue=08000&article=00014&type=abstract Garcia et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycles'''

===References===
# Garcia AA, Blessing JA, Vaccarello L, Roman LD; Gynecologic Oncology Group Study. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol. 2007 Aug;30(4):428-31. [http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=2007&issue=08000&article=00014&type=abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17762444 PubMed]
# Garcia AA, Blessing JA, Nolte S, Mannel RS; Gynecologic Oncology Group. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol Oncol. 2008 Oct;111(1):22-6. [http://www.gynecologiconcology-online.net/article/S0090-8258(08)00452-6/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18675446 PubMed]

==Fluorouracil & Folinic acid {{#subobject:e38061|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 1850/200 {{#subobject:937680|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://journals.lww.com/amjclinicaloncology/Fulltext/1996/10000/A_Phase_II_Trial_of_5_Fluorouracil_and_High_Dose.2.aspx Look et al. 1996]
|style="background-color:#91cf61"|Phase II
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(97)94886-1/abstract Look et al. 1997]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: it is not entirely clear from these publications whether leucovorin is given on day 1 only, versus on days 1 to 5.''
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 370 mg/m<sup>2</sup> IV bolus over 5 minutes once per day on days 1 to 5, '''given second'''
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV bolus once on day 1 (see note), '''given first'''

'''28-day cycle for 2 cycles, then 35-day cycles'''

===Variant #2, 2125/100 {{#subobject:c76c92|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/1449112 Look et al. 1992]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 425 mg/m<sup>2</sup> IV once per day on days 1 to 5, '''given second'''
*[[Folinic acid (Leucovorin)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 5, '''given first'''

'''28-day cycle for 2 cycles, then 35-day cycles'''

===References===
# Look KY, Blessing JA, Muss HB, Partridge EE, Malfetano JH. 5-fluorouracil and low-dose leucovorin in the treatment of recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol. 1992 Dec;15(6):497-9. [https://www.ncbi.nlm.nih.gov/pubmed/1449112 PubMed]
# Look KY, Blessing JA, Gallup DG, Lentz SS. A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol. 1996 Oct;19(5):439-41. [https://journals.lww.com/amjclinicaloncology/Fulltext/1996/10000/A_Phase_II_Trial_of_5_Fluorouracil_and_High_Dose.2.aspx link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8823469 PubMed]
# Look KY, Blessing JA, Valea FA, McGehee R, Manetta A, Webster KD, Andersen WA. Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1997 Dec;67(3):255-8. [http://www.gynecologiconcology-online.net/article/S0090-8258(97)94886-1/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9441772 PubMed]

==Gemcitabine monotherapy {{#subobject:313d78|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9f6038|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(99)95671-8/abstract Schilder et al. 2000 (GOG 127-K)]
|style="background-color:#91cf61"|Phase II
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(04)00773-5/abstract Schilder et al. 2005]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15

'''28-day cycles'''

===References===
# Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Feb;76(2):204-7. [http://www.gynecologiconcology-online.net/article/S0090-8258(99)95671-8/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10637071 PubMed]
# Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2005 Jan;96(1):103-7. [http://www.gynecologiconcology-online.net/article/S0090-8258(04)00773-5/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15589587 PubMed]

==Irinotecan monotherapy {{#subobject:e80134|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:fe2b8e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/15/2/625.long Verschraegen et al. 1997]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1, 8, 15, 22

====Supportive medications==== 
*[[Diphenhydramine (Benadryl)]] 25 to 50 mg IV or PO every 6 hours as needed for diarrhea during irinotecan infusion
*Atropine 1 mg IV every 6 hours as needed for diarrhea during irinotecan infusion
*[[Loperamide (Imodium)]] 4 mg PO as needed for each episode of delayed diarrhea between irinotecan infusions

'''42-day cycles'''

===References===
# Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 1997 Feb;15(2):625-31. [http://jco.ascopubs.org/content/15/2/625.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9053486 PubMed]

==Pembrolizumab monotherapy {{#subobject:e0d17a|Regimen=1}}==
===Regimen {{#subobject:7b36e9|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.5514 Schellens et al. 2017 (KEYNOTE-158)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Immunotherapy====
*[[Pembrolizumab (Keytruda)]] 200 mg IV over 30 minutes once on day 1

'''21-day cycle for up to 2 years'''

===References===
# '''Abstract:''' Jan H.M. Schellens, Aurelien Marabelle, Susan Zeigenfuss, Jie Ding, Scott Knowles Pruitt, and Hyun Cheol Chung. Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study. Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 5514-5514. [http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.5514 link to abstract]

==Pemetrexed monotherapy {{#subobject:57456b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:db8999|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(08)00203-5/abstract Miller et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pemetrexed (Alimta)]] 900 mg/m<sup>2</sup> IV over 10 minutes once on day 1

====Supportive medications====
*Folic acid 350 to 600 mcg PO once per day, starting 7 days before pemetrexed, to continue throughout therapy
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM once 7 days before pemetrexed, then 1000 mcg IM every 9 weeks
*[[Dexamethasone (Decadron)]] 4 mg PO twice per day the day before, the day of, and day after pemetrexed
*No NSAIDs (nonsteroidal anti-inflammatory drugs) for 2 days before or after pemetrexed

'''21-day cycles'''

===References===
# Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO; Gynecologic Oncology Group. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Jul;110(1):65-70. Epub 2008 May 5. [http://www.gynecologiconcology-online.net/article/S0090-8258(08)00203-5/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18455781 PubMed]

==Vinorelbine monotherapy {{#subobject:2186af|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:ba6a7e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(03)00770-4/abstract Muggia et al. 2004]
|style="background-color:#91cf61"|Phase II
|ORR: 14% (95% CI 5-27%)
|-
|[http://www.gynecologiconcology-online.net/article/S0090-8258(04)00774-7/abstract Muggia et al. 2005]
|style="background-color:#91cf61"|Phase II
|ORR: 7%
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycles'''

===References===
# Muggia FM, Blessing JA, Method M, Miller DS, Johnson GA, Lee RB, Menzin A; Gynecologic Oncology Group study. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Feb;92(2):639-43. [http://www.gynecologiconcology-online.net/article/S0090-8258(03)00770-4/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14766259 PubMed]
# Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk BJ, Sorosky J, Pearl ML. Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005 Jan;96(1):108-11. [http://www.gynecologiconcology-online.net/article/S0090-8258(04)00774-7/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15589588 PubMed]

[[Category:Cervical cancer regimens]]
[[Category:Disease-specific pages]]
[[Category:Gynecologic cancers]]
